Campion Océane, Thevenard Devy Jessica, Billottet Clotilde, Schneider Christophe, Etique Nicolas, Dupuy Jean-William, Raymond Anne-Aurélie, Boulagnon Rombi Camille, Meunier Marie, Djermoune El-Hadi, Lelièvre Elodie, Wahart Amandine, Bour Camille, Hachet Cathy, Cairo Stefano, Bikfalvi Andréas, Dedieu Stéphane, Devy Jérôme
UFR Sciences Exactes et Naturelles, Université de Reims Champagne-Ardenne, 51687 Reims, France.
Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, UMR 7369 CNRS, 51687 Reims, France.
Biomedicines. 2021 Oct 9;9(10):1430. doi: 10.3390/biomedicines9101430.
LRP-1 is a multifunctional scavenger receptor belonging to the LDLR family. Due to its capacity to control pericellular levels of various growth factors and proteases, LRP-1 plays a crucial role in membrane proteome dynamics, which appears decisive for tumor progression.
LRP-1 involvement in a TNBC model was assessed using an RNA interference strategy in MDA-MB-231 cells. In vivo, tumorigenic and angiogenic effects of LRP-1-repressed cells were evaluated using an orthotopic xenograft model and two angiogenic assays (Matrigel plugs, CAM). DCE-MRI, FMT, and IHC were used to complete a tumor longitudinal follow-up and obtain morphological and functional vascular information. In vitro, HUVECs' angiogenic potential was evaluated using a tumor secretome, subjected to a proteomic analysis to highlight LRP-1-dependant signaling pathways.
LRP-1 repression in MDA-MB-231 tumors led to a 60% growth delay because of, inter alia, morphological and functional vascular differences, confirmed by angiogenic models. In vitro, the LRP-1-repressed cells secretome restrained HUVECs' angiogenic capabilities. A proteomics analysis revealed that LRP-1 supports tumor growth and angiogenesis by regulating TGF-β signaling and plasminogen/plasmin system.
LRP-1, by its wide spectrum of interactions, emerges as an important matricellular player in the control of cancer-signaling events such as angiogenesis, by supporting tumor vascular morphology and functionality.
LRP-1是一种属于低密度脂蛋白受体(LDLR)家族的多功能清道夫受体。由于其能够控制多种生长因子和蛋白酶的细胞周水平,LRP-1在膜蛋白质组动力学中发挥关键作用,这对肿瘤进展似乎具有决定性意义。
在MDA-MB-231细胞中使用RNA干扰策略评估LRP-1在三阴性乳腺癌(TNBC)模型中的作用。在体内,使用原位异种移植模型和两种血管生成测定法(基质胶塞、鸡胚绒毛尿囊膜)评估LRP-1抑制细胞的致瘤和血管生成作用。使用动态对比增强磁共振成像(DCE-MRI)、荧光分子断层成像(FMT)和免疫组织化学(IHC)完成肿瘤纵向随访并获得形态学和功能性血管信息。在体外,使用肿瘤分泌组评估人脐静脉内皮细胞(HUVECs)的血管生成潜力,并对其进行蛋白质组学分析以突出LRP-1依赖性信号通路。
MDA-MB-231肿瘤中LRP-1的抑制导致生长延迟60%,这尤其是由于血管生成模型证实的形态学和功能性血管差异。在体外,LRP-1抑制细胞的分泌组抑制了HUVECs的血管生成能力。蛋白质组学分析表明,LRP-1通过调节转化生长因子-β(TGF-β)信号传导和纤溶酶原/纤溶酶系统来支持肿瘤生长和血管生成。
LRP-1通过其广泛的相互作用,通过支持肿瘤血管形态和功能,成为控制诸如血管生成等癌症信号事件的重要基质细胞因子。